Prime Medicine Forecast, price target & analysts
Prime Medicine Target price 2025 - Analyst rating & recommendation
Prime Medicine Classifications & Recommendation:
Prime Medicine Price Target
| Target Price | $8.16 |
| Price | $4.13 |
| Potential |
97.58%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Prime Medicine 2026 .
The average Prime Medicine target price is $8.16.
This is
97.58%
register free of charge
$12.60
205.08%
register free of charge
$1.52
63.32%
register free of charge
|
|
| A rating was issued by 18 analysts: 14 Analysts recommend Prime Medicine to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Prime Medicine stock has an average upside potential 2026 of
97.58%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.98 | 6.09 |
| 104.33% | ||
| EBITDA Margin | -6,588.59% | -2,850.34% |
| 56.74% | ||
| Net Margin | -6,573.15% | -2,848.14% |
| 56.67% |
14 Analysts have issued a sales forecast Prime Medicine 2025 . The average Prime Medicine sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Prime Medicine EBITDA forecast 2025. The average Prime Medicine EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Prime Medicine Analysts have issued a net profit forecast 2025. The average Prime Medicine net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.65 | -1.32 |
| 24.31% | 20.00% | |
| P/E | negative | |
| EV/Sales | 67.53 |
14 Analysts have issued a Prime Medicine forecast for earnings per share. The average Prime Medicine EPS is
This results in the following potential growth metrics and future valuations:
Current Prime Medicine Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | May 27 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 20 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | May 20 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | May 20 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 19 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
May 27 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 19 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
